Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult
Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells
Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism
SB203580 increases G-CSF production via a stem-loop destabilizing element in the 3’ untranslated region in macrophages independently of its effect on p38 MAPK activity
Blockade by SB203580 ofCyp1a1Induction by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, and the Possible Mechanism: Possible Involvement of the p38 Mitogen-Activated Protein Kinase Pathway in Shuttling of Ah Receptor Overexpressed in COS-7 Cells
